These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9759192)

  • 21. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
    Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
    Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. American Academy of Pediatrics Committee on Infectious Diseases.
    Pediatrics; 1997 Feb; 99(2):282-8. PubMed ID: 9024463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
    Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
    Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials.
    Cherry JD
    Pediatr Infect Dis J; 1997 Apr; 16(4 Suppl):S90-6. PubMed ID: 9109163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand.
    Radke S; Petousis-Harris H; Watson D; Gentles D; Turner N
    Vaccine; 2017 Jan; 35(1):177-183. PubMed ID: 27866766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age.
    Bernstein DI; Smith VE; Schiff GM; Rathfon HM; Boscia JA
    Pediatr Infect Dis J; 1993 Feb; 12(2):131-5. PubMed ID: 8426770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
    Olin P; Rasmussen F; Gustafsson L; Hallander HO; Heijbel H
    Lancet; 1997 Nov; 350(9091):1569-77. PubMed ID: 9393335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whooping cough, twenty years from acellular vaccines introduction.
    Greco D; Esposito S; Tozzi A; Pandolfi E; Icardi G; Giammanco A
    Ann Ig; 2015; 27(2):415-31. PubMed ID: 26051141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Booster vaccination after neonatal priming with acellular pertussis vaccine.
    Knuf M; Schmitt HJ; Jacquet JM; Collard A; Kieninger D; Meyer CU; Siegrist CA; Zepp F
    J Pediatr; 2010 Apr; 156(4):675-8. PubMed ID: 20303444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses.
    Sheridan SL; Ware RS; Grimwood K; Lambert SB
    Vaccine; 2015 Sep; 33(39):5027-30. PubMed ID: 26297874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines.
    Edwards KM; Decker MD; Bradley RB; Taylor JC; Hager CC
    Pediatr Infect Dis J; 1991 Apr; 10(4):315-8. PubMed ID: 2062628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
    Maertens K; Hoang TT; Nguyen TD; Caboré RN; Duong TH; Huygen K; Hens N; Van Damme P; Dang DA; Leuridan E
    Clin Infect Dis; 2016 Dec; 63(suppl 4):S197-S204. PubMed ID: 27838673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.